SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending intensely as the community eagerly awaits the imminent launch of its next-generation BlueBird 6 satellite, seen as a crucial "scale-up proof point" for its space-based cellular network. The "SpaceMob" is buzzing with excitement, discussing the company's long-term potential and market impact, with many dismissing concerns that the event is already "priced in." This highly anticipated launch is generating strong bullish sentiment, positioning ASTS as a key player in the evolving space sector.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending due to widespread anticipation surrounding the outcome of a recent FDA meeting concerning its lead drug, Sonelokimab, for Hidradenitis Suppurativa. The community largely expects a positive regulatory update, which many believe would significantly de-risk the asset. This has intensified discussions about a potential acquisition by a major pharmaceutical player, fueled by reported prior interest and recent executive share conversions interpreted by some as preparatory for a substantial transaction.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is trending with intense anticipation surrounding a pivotal FDA decision for its drug Narsoplimab (Yartemlea) by December 26th, targeting a life-threatening condition without an approved treatment. This binary event is bolstered by the recent closing of a significant deal with Novo Nordisk, bringing in substantial upfront cash and potential future milestones, along with a $100 million share repurchase program, fueling community expectations for a transformative approval and a notable short squeeze.

TOSHI

TOSHI is trending prominently, sparking community discussion around its price dips even as a loyal base actively accumulates, viewing it as a prime accumulation opportunity. Holders maintain strong conviction in its long-term potential as the "Face of Base" blockchain, driven by existing major exchange presence and anticipated future utility developments.

Churchill Capital Corp. X is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Michael Klein on January 4, 2024 and is headquartered in New York, NY.

Churchill Capital Corp X - Ordinary Shares - Class A

Churchill Capital Corp X 

Churchill Capital Corp X (CCCX) is trending amid strong community buzz surrounding its upcoming merger with Infleqtion, a quantum technology leader. Investors are highlighting Infleqtion's established partnerships with defense and aerospace entities, along with its commercially viable quantum sensing and timing solutions, which many believe are significantly undervalued compared to sector peers. The sentiment suggests anticipation for substantial institutional investment and accelerated growth once the ticker changes post-merger.

Starfighters Space Inc

Starfighters Space Inc. (FJET) is experiencing extreme volatility following its recent IPO, igniting intense community debate. Bulls highlight its low float and aerospace sector exposure as potential catalysts for a massive squeeze, while skeptics label it a pump-and-dump, raising concerns about its valuation, pre-revenue status, and the qualifications of its R&D team. The stock's dramatic price swings and unusually high short borrow fees are central to the ongoing, heated discussion.

Ascent Solar Technologies, Inc. engages in the design, development, and manufacture of solar technology and power solutions for remote locations and extreme environments. It integrates photovoltaic modules into a variety of applications such as aerospace, defense, transportation, and electronic products. The company was founded by Mohan S. Misra and Joseph H. Armstrong on October 18, 2005 and is headquartered in Thornton, CO.

Ascent Solar Technologies Inc

Ascent Solar Technologies is generating buzz following a series of strategic teaming agreements that position its specialized thin-film solar technology for critical applications across the growing space, aerospace, and defense sectors. The community is actively debating the stock's high volatility and long-term potential for significant contracts, with discussions weighing its innovative solar solutions for lunar missions and drone powering against concerns about its historical dilution.

Sable Offshore Corp. engages in offshore oil and gas field operations. It focuses on developing the prolific Santa Ynez Unit in federal waters offshore California. The company was founded by James C. Flores on October 16, 2020 and is headquartered in Houston, TX.

Sable Offshore Corp.

Sable Offshore Corp. is trending after receiving federal regulatory approval to restart its Las Flores Pipeline System, a move perceived as a crucial step toward reactivating its California offshore oil assets under federal oversight. This development has spurred significant community discussion, with many investors anticipating substantial upside and a potential short squeeze, while others remain cautious due to the company's financial concerns and the likelihood of continued state-level legal and permitting challenges.

Avantis is the largest RWA perps DEX in DeFi, built on and backed by Base. Avantis allows users to trade crypto and real-world assets (RWAs), including FX, commodities, indices, and equities. Backed by Pantera and Coinbase, Avantis is the largest DEX on Base by volumes, and brings institutional-grade products to DeFi, letting users trade with up to 500x leverage in a transparent, permissionless environment.  Avantis is best known for launching zero-fee perpetuals (ZFP) — a first-of-its-kind primitive where traders only pay fees if they profit. They've also brought leveraged RWAs onchain. This has driven explosive growth: over $20B+ in cumulative volume and 15M+ run-rate revenues since Febrruary 2024.

Avantis

AVNT CRYPTO is generating significant buzz due to its recent Robinhood listing and deep integration with the Coinbase Base app, leading many to anticipate substantial gains and a potential short squeeze given its low float. However, a polarized community also voices strong skepticism, citing concerns over ongoing token unlocks and past price instability, with some labeling it a "rug pull." This divided sentiment underscores the highly speculative nature of the token amid intense competition among decentralized exchanges.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum is trending due to anticipation surrounding its showcase of commercial quantum computing solutions and real-world applications at an upcoming major tech event, fueling speculation about its "quantum supremacy" in optimization. The community is actively debating its potential as a generational technology, drawing comparisons to early AI, while skeptics point to its current low revenue, cash burn, and perceived overvaluation amidst allegations of manipulated "pump and dump" cycles.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Neurocrine Biosciences Provides Update on Phase 3 Study of Valbenazine in Dyskinetic Cerebral Palsy

Neurocrine Biosciences Provides Update on Phase 3 Study of Valbenazine in Dyskinetic Cerebral Palsy Neurocrine Biosciences Provides Update on Phase 3 Study of Valbenazine in Dyskinetic Cerebral Palsy...

Assenagon Asset Management S.A. Sells 13,280 Shares of Neurocrine Biosciences, Inc. $NBIX

Assenagon Asset Management S.A. cut its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 22.0% in the 3rd quarter, according to its most recent 13F filing with the Securities and...

Neurocrine Biosciences (NASDAQ:NBIX) Director Leslie Norwalk Sells 1,190 Shares

Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Get Free Report) Director Leslie Norwalk sold 1,190 shares of the business's stock in a transaction dated Tuesday, December 16th. The stock was sold at an...

Neurocrine Biosciences (NASDAQ:NBIX) Director Leslie Norwalk Sells 5,000 Shares

Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Get Free Report) Director Leslie Norwalk sold 5,000 shares of the stock in a transaction on Monday, December 15th. The stock was sold at an average price...

Neurocrine Biosciences (NASDAQ:NBIX) Stock Price Expected to Rise, HC Wainwright Analyst Says

HC Wainwright increased their target price on shares of Neurocrine Biosciences from $168.00 to $198.00 and gave the stock a "buy" rating in a research note on Wednesday...

Texas Permanent School Fund Corp Sells 11,976 Shares of Neurocrine Biosciences, Inc. $NBIX

Texas Permanent School Fund Corp cut its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 18.2% in the 2nd quarter, according to its most recent filing with the Securities and...

Neurocrine Biosciences Showcases R&D Transformation Driving Innovation Across Neuroscience and Endocrinology

Neurocrine Biosciences Showcases R&D Transformation Driving Innovation Across Neuroscience and Endocrinology Neurocrine Biosciences Showcases R&D Transformation Driving Innovation Across Neuroscience...

Hudson Bay Capital Management LP Has $9.75 Million Stake in Neurocrine Biosciences, Inc. $NBIX

Hudson Bay Capital Management LP trimmed its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 48.4% during the 2nd quarter, according to the company in its most...

Neurocrine Biosciences (NASDAQ:NBIX) Stock Price Expected to Rise, Mizuho Analyst Says

Mizuho upped their target price on shares of Neurocrine Biosciences from $146.00 to $175.00 and gave the company a "neutral" rating in a research note on Friday...

Boone Capital Management LLC Makes New Investment in Neurocrine Biosciences, Inc. $NBIX

Boone Capital Management LLC bought a new stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with...

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	$1.86	--	--	N/A
Q3 '25	$1.59	$2.04	28.53%	BEAT
Q2 '25	$0.96	$1.06	9.89%	BEAT
Q1 '25	$0.54	$0.08	-85.05%	MISSED
Q4 '24	$1.58	$1.00	-36.78%	MISSED

NBIX
Neurocrine Biosciences, Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest NBIX News

NBIXNeurocrine Biosciences, Inc.